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Abstract. The stromal derived factor-1 (SDF-1)/CXCR4 
axis is associated with tumor aggressiveness and metastasis 
in prostate cancer. The present study aimed to explore the 
potential therapeutic effects of a CXCR4 antagonist in prostate 
cancer. The effect of SDF‑1 and a CXCR4‑specific antagonist, 
AMD3100, on human prostate cancer PC-3 cell proliferation 
and protein kinase B (Akt) signaling was assessed. Moreover, 
a PC-3 tumor xenograft model was used to evaluate the effect 
of AMD3100 on tumor growth and to identify the histo-
pathological changes and immunohistochemical differences 
between AMD3100-treated and untreated groups. Cell prolif-
eration was not significantly affected by SDF‑1 or AMD3100 
treatment in vitro. Western blot analysis revealed that SDF-1 
stimulation enhanced the expression of phosphorylated Akt 
in the PC-3 cells, but that the SDF-1-induced expression of 
phosphorylated Akt was abrogated in the AMD3100-treated 
PC-3 cells. In the PC-3 tumor xenograft model, AMD3100 
significantly inhibited tumor growth, while AMD3100‑treated 
PC-3 tumors had lower levels of microvessel formation and 
a lower immunoreactivity for the proliferation marker Ki-67 
and the anti-apoptotic marker Bcl-2 compared to control 
tumors in vivo. The CXCR4-specific antagonist inhibits 
SDF-1-induced CXCR4/Akt signal transduction, and effec-
tively suppresses tumor growth in the PC-3 xenograft model. 
The present study indicates that CXCR4 targeting may repre-
sent a novel strategy for the treatment of castration-resistant 
prostate cancer (CRPC).
Introduction
Radical surgery or radiotherapy may be curative therapies for 
patients with localized prostate cancer, but there are no effec-
tive treatment modalities for the management of advanced 
prostate cancer. Androgen deprivation treatment is the most 
effective systemic approach for patients with metastatic 
disease. Although 80-90% of patients initially respond favor-
ably to this treatment, they eventually become unresponsive to 
androgen deprivation and develop castration-resistant prostate 
cancer (CRPC) (1,2). Currently, the combination of docetaxel 
and prednisone is considered the standard first‑line therapy for 
CRPC, but the survival gain from docetaxel chemotherapy is 
limited and unsatisfactory (3).
Stromal derived factor-1 (SDF-1) is a member of the CXC 
subfamily of chemokines that interacts with the 7 transmem-
brane G-protein-coupled receptor CXCR4 (4-6). CXCR4 
expression has been reported in at least 23 epithelial, mesen-
chymal and hematopoietic cancers, indicating the importance 
of this ligand/receptor axis in tumor aggressiveness and 
metastasis (7-9). The role of the SDF-1/CXCR4 axis in prostate 
cancer has been experimentally demonstrated. It is known that 
CXCR4 mRNA and protein are expressed in prostate cancer 
cell lines, including LNCaP, PC-3 and DU145, and in human 
prostate samples (10). Akashi et al (11) demonstrated that 
patients with a high level of CXCR4 expression in the tumor 
had worse cancer‑specific survival rates than patients with a 
low level of expression. Darash-Yahana et al (12) reported that 
subcutaneous xenografts of prostate tumors that overexpressed 
CXCR4 in nude mice were 2- to 3-fold larger in volume and 
weight compared to the controls. Moreover, the blood vessel 
density, invasiveness of the tumors and metastasis to the lymph 
nodes and lungs were significantly increased in these tumors. In 
the present study, the potential therapeutic effects of the CXCR4 
antagonist were explored in a prostate cancer xenograft model.
Materials and methods
Cell culture and reagents. Human prostate cancer PC-3 cells, 
which are representative of CRPC cells, were obtained from 
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the Korea Cell Line Bank (Seoul, Korea). These cells were 
maintained in RPMI-1640 supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin-streptomycin and 1% L-glutamine. 
All cells were grown in a humidified incubator at 37˚C and 5% 
CO2. SDF-1 (R&D Systems, Minneapolis, MN, USA) was used 
as a specific ligand for CXCR4, and the bicyclam derivative, 
AMD3100 (Sigma-Aldrich, St. Louis, MO, USA), was used 
as a CXCR4‑specific antagonist. In certain experiments, the 
cells were pretreated with filipin (Sigma‑Aldrich) to deplete 
membrane cholesterol (13).
In vitro proliferation assay. The PC-3 cells were seeded at a 
density of 2x103 cells/well into 96-well plates in culture medium 
containing 10% FBS. After 24 h, the cells were washed and 
cultured with serum-free medium alone (control) or with 
medium containing SDF-1 or AMD3100 at various concentra-
tions. After 72 h, the number of viable cells was counted using 
a CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI, USA) according to the manufacturer's 
instructions. This assay is based on the ability of viable cells to 
bioreduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymetho-
xyphenyl)-2-(4-sulfonyl)-2H-tetrazolium to formazan in the 
presence of phenazine methosulfate, an electron-coupling 
reagent. Formazan production was quantified by measuring 
absorbance at 490 nm, which is directly proportional to the 
number of living cells.
Western blot analysis. Prostate cancer cells were cultured to 
subconfluence (80‑90%), washed and incubated in serum‑free 
media for 12 h. SDF-1 stimulation was performed with 
0-200 ng/ml SDF-1 for various lengths of time. In certain experi-
ments, 1 µg/ml AMD3100 or 1 µg/ml filipin was pre‑incubated 
with the cells. The cells were lysed with radio-immunopre-
cipitation assay (RIPA) lysis buffer consisting of 50 mM 
HEPES (pH 7.6; USB, Cleveland, OH, USA), 150 mM NaCl 
(Sigma-Aldrich), 1% NP-40, 10 ml/ml phenylmethylsulfonyl 
fluoride (both Amresco, Solon, OH, USA) and 10 ml/ml 
aprotinin (Sigma-Aldrich), and cleared by centrifugation at 
12,000 x g. The protein concentration was determined using a 
detergent compatible protein assay kit (Bio-Rad Laboratories, 
Hercules, CA, USA). Equal amounts of cell lysates were sepa-
rated by 10-12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes. 
The membranes were blocked for 1 h at room temperature 
in 5% skimmed dried milk and incubated for 2 h at room 
temperature with anti-protein kinase B (Akt)1 (1:1,000), 
anti-p-Akt1/2/3 (1:1,000) or β-actin (1:2,000) antibodies (all 
from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). 
The membranes were incubated with horseradish peroxidase 
(HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) 
or goat anti-mouse IgG for 1 h at room temperature. Protein 
signals were detected by chemiluminescence with ECL detec-
tion reagents (Amersham Biosciences, Piscataway, NJ, USA).
Xenografts in nude mice. All the protocols for the animal 
studies were reviewed and approved by the Institutional 
Animal Care and Use Committee at Yonsei University College 
of Medicine. Six-week-old male nude mice (BALB/c) were 
obtained from Japan SLC (Hamamatsu, Japan). The PC-3 
cells (5x106 cells/mouse) were injected subcutaneously into 
the right dorsal region. When the tumors measured 40 mm3, 
the mice were randomized to receive AMD3100 (n=6; 
3 mg/kg) or vehicle alone (n=6; phosphate-buffered saline) 
by intraperitoneal injection for 5 consecutive days/week for 
4 weeks. Tumor diameters were measured at regular intervals 
using calipers. The tumor volume (V) was calculated using the 
following formula: V = A x B2 / 2 (A, axial diameter; B, rota-
tional diameter). Tumors were excised and fixed overnight in 
neutral-buffered formalin and processed by routine methods.
Immunohistochemistry. Immunohistochemical staining was 
performed using the mouse anti-human Ki-67 monoclonal 
antibody (1:50), the mouse anti-human Bcl-2 antibody 
(prediluted form; both from Dako, Carpinteria, CA, USA) 
and the rabbit anti-mouse CD34 monoclonal antibody (1:100; 
BD Pharmingen, San Jose, CA, USA) in a xenograft tissue 
experiment. In brief, formalin-fixed, paraffin-embedded 
4‑µm specimens were deparaffinized and rehydrated. The 
sections were treated with 2% hydrogen peroxide to inac-
tivate endogenous peroxidase, and non-specific binding 
was blocked by treatment with the blocking reagent. The 
primary antibody was applied to each section for 1 h at 
37˚C, and the appropriate HRP-conjugated secondary 
antibody was applied at a dilution of 1:100 for 1 h at room 
temperature. Immunoreactivity was subsequently detected 
using a 3,3'-diaminobenzidine system (Vector Laboratories, 
Burlingame, CA, USA). Nuclei were counterstained using 
Meyer's hematoxylin.
Data analysis. Statistical comparisons were performed among 
groups using Student's t-test or the Mann-Whitney U test. 
P<0.05 was considered to indicate a statistically significant 
difference. The Statistical Package for Social Sciences (SPSS), 
version 12.0 for Windows, was used for the statistical analysis. 
Data are expressed as the mean ± standard deviation. All 
in vitro experiments were repeated with triplicate or quadru-
plicate samples and similar results were obtained across all 
trials.
Results
Effect of SDF‑1 and a CXCR4 antagonist on prolifera‑
tion of PC‑3 cells. Subsequent to incubation for 72 h, PC-3 
cell proliferation was not significantly affected by SDF‑1 at 
concentrations ranging between 50 and 200 ng/ml. AMD3100 
also showed no inhibitory effect on PC-3 cell proliferation at 
concentrations ≤0.5 µg/ml. Although cell proliferation was 
marginally suppressed at 1 and 10 µg/ml, the effect was not 
statistically significant (Fig. 1).
Effect of a CXCR4 antagonist on SDF‑1/CXCR4‑mediated 
Akt signaling in PC‑3 cells. Following SDF-1 stimula-
tion, the expression of phosphorylated Akt was enhanced 
in the PC-3 cells at 30, 60 and 180 min compared with the 
control. The highest levels of Akt phosphorylation following 
SDF-1 stimulation were observed between 30 and 60 min. 
The expression of pAkt induced by SDF-1 was marginally 
increased in the AMD3100-treated PC-3 cells compared to 
the controls, but the levels did not reach those expressed in 
the PC-3 cells stimulated by SDF-1 alone. Examination of the 
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total Akt levels demonstrated that almost all of the conditions 
resulted in similar levels of Akt (Fig. 2). These results indicate 
that the CXCR4-specific antagonist AMD3100 abrogates 
SDF-1-induced pAkt activation.
Blocking CXCR4 suppresses the tumor growth of prostate 
cancer in a xenograft mouse model. The tumor volumes of 
the AMD3100-treated and control groups were 49.0±16.7 and 
102.5±20.9 mm3 on day 7 post-treatment, 54.9±19.4 and 
234.0±92.9 mm3 on day 14, 56.3±18.5 and 559.9±167.8 mm3 
on day 21 and 42.9±18.4 and 751.9±276.4 mm3 on day 28, 
respectively (Fig. 3). These data indicate that the CXCR4 
antagonist used here delayed tumor growth at an early stage 
of tumor development. There was no difference in the body 
weight between the 2 groups until day 21, however, the body 
weight on day 28 was 22.4±0.7 g in the AMD3100-treated 
group and 21.1±0.7 g in the control group, and this difference 
was significant (Fig. 3).
Histopathological examination of PC‑3 xenograft tumors 
following CXCR4 antagonist treatment. Hematoxylin and 
eosin (HE) staining revealed a definite histological change 
in the PC-3 xenograft tumors following treatment with the 
CXCR4 antagonist (Fig. 4). CXCR4 antagonist-treated tumors 
were characterized by their spindle cell shapes compared with 
the control tumors, as well as their enlarged, pleomorphic 
and hyperchromatic nuclei. Immunohistochemistry for Bcl-2 
expression showed brownish cytoplasmic staining in the two 
groups, but Bcl-2 immunostaining was more predominant and 
more frequently observed in the control tumors (Fig. 4). The 
Figure 3. Effects of a CXCR4 antagonist on human prostate cancer PC-3 
tumors in vivo. (A) Body weights and (B) tumor volumes of vehicle-treated 
(n=6) and CXCR4 antagonist-treated (n=6) nude mice are shown. The body 
weights and tumor volumes of the mice were measured at days 7, 14, 21 and 
28. Points, mean; bar, standard deviation; *P<0.05 and **P<0.01, vs. vehicle. 
(C) Tumors were excised and images were captured, and the representative 
examples of PC-3 tumors are shown.
Figure 1. Effects of (A) stromal derived factor-1 (SDF-1) and (B) a CXCR4 
antagonist on human prostate cancer PC-3 cell proliferation. Points, mean; 
bar, standard deviation. There was no statistically significant difference 
among groups. SDF-1, stromal derived factor-1.
Figure 2. Effects of a CXCR4 antagonist and cholesterol depleting agent on 
stromal derived factor-1 (SDF-1)/CXCR4-mediated protein kinase B (Akt) 
signaling in human prostate cancer PC-3 cells. Serum-starved PC-3 cells 
were stimulated by 200 ng/ml SDF-1 for 0, 30, 60 and 180 min. In certain 
cases, serum‑starved PC‑3 cells were pretreated with filipin or AMD3100 
prior to SDF-1 stimulation. SDF-1, stromal derived factor-1.
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immunohistochemistry for CD34 was examined on the primary 
tumor tissue sections to determine whether the suppression of 
primary tumor growth was a result of an antiangiogenic effect 
(i.e., the inhibition of microvessel formation) of the CXCR4 
antagonist. A marked reduction in microvessel formation 
was observed in the tumors of the CXCR4 antagonist-treated 
mice (Fig. 4).
Ki-67 was used as an estimator of tumor aggressiveness, 
with dark red-brown nuclear staining regarded as positivity for 
Ki‑67. The Ki‑67 staining index was significantly higher in 
the control tumors compared to the CXCR4 antagonist-treated 
tumors (10.2±1.9 vs. 28.5±4.7%, respectively; P<0.05; 
Figs. 4 and 5).
Discussion
The present study observed that a CXCR4‑specific antagonist 
effectively inhibited CXCR4/Akt signal transduction in PC-3 
cells, as well as tumor growth in nude mice challenged with 
PC-3 cells. This indicates that CXCR4 targeting may represent 
a novel, effective strategy for the treatment of human prostate 
cancer.
It is well known that the binding of chemokines to their 
G protein-linked receptors on target cells leads to a series of 
signal transduction events involving the generation of inositol 
1,4,5-trisphosphate and cyclic adenosine monophosphate-depen-
dent protein kinase, the activation of phosphatidylinositol 
3-kinase (PI3K), the phosphorylation of protein kinase B (Akt) 
and extracellular signal-regulated kinase (ERK), the elevation 
of components of focal adhesion complexes and the activation 
of protein kinase C (14). SDF-1 binding to CXCR4 generates 
various signaling mechanisms affecting the regulation of angio-
genesis, the activation of cell invasion, the promotion of cell 
growth, the inhibition of apoptosis, and notably, is important in 
metastasis (15-20). In a previous study of prostate cancer, differ-
ential activation of the ERK and PI3K/Akt pathways resulted 
in differential secretion of interleukin (IL)-6, IL-8, tissue 
inhibitors of matrix metalloproteinase-2 (MMP-2) and vascular 
endothelial cell growth factor, which affected the ability of the 
cancer cells to induce angiogenesis (15). Exogenous SDF-1 
induces Akt phosphorylation in PC-3 cells, which is indepen-
dent of PI3K and indispensable for MMP-9 secretion, migration 
and invasion (16). SDF-1 induction enhances various MMPs 
(MMP-1, -2, -3, -9, -11, -13 and -14) in PC-3 cells (17). It has also 
been reported that the SDF-1-induced expression of CXCR4 
in PC-3 cells is dependent on the mitogen-activated protein 
kinase (MEK)/ERK signaling cascade and on nuclear factor-κB 
(NF-κB) activation, which enhances endothelial adhesion and 
transendothelial migration (18). An immunohistochemical 
study of human samples demonstrated that high NF-κB expres-
sion was associated with CXCR4 expression and that they are 
co-expressed in approximately one-third of patients with clini-
cally localized prostate cancer (19). Wang et al (20) also showed 
that CXCR4 plays a significant role in prostate cancer metastasis 
through the upregulation of vascular endothelial growth factor 
(VEGF).
Figure 4. Histopathological examination of human prostate cancer PC-3 
xenograft tumors following treatment with a vehicle or CXCR4 antagonist. 
Hematoxylin and eosin (HE) staining in (A) vehicle-treated and (B) CXCR4 
antagonist-treated tumors. Immunohistochemistry of Bcl-2 in (C) vehicle-treated 
and (D) CXCR4 antagonist-treated tumors. Ki-67 in (E) vehicle-treated 
and (F) CXCR4 antagonist-treated tumors. CD34 in (G) vehicle-treated and 
(H) CXCR4 antagonist-treated tumors. (C and D) Immunohistochemistry for 
Bcl-2 expression showed brownish cytoplasmic staining. (E and F) For Ki-67, 
dark red-brownish nuclear staining was regarded as positivity. (G and H) There 
was a marked reduction in microvessel formation in the tumors of the CXCR4 
antagonist-treated mice compared with those of the control group. Original 
magnifications (A‑F) x200; (G and H) x100.
Figure 5. Ki-67 staining index of human prostate cancer PC-3 xenograft 
tumors following treatment with vehicle or CXCR4 antagonist. Points, mean; 
bar, standard deviation; *P<0.05 vs. vehicle.
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The present study showed that SDF-1 has no direct effects 
on PC‑3 cell proliferation. These findings are in accordance 
with results from previous studies of other types of cells, 
showing that SDF-1 has no proliferative effect on glioma 
(U251n), cholangiocarcinoma (RMCCAI and KKU100), 
testicular germ cell tumor (TCAM2), rhabdomyosarcoma and 
pancreatic cancer cells (21-25). Notably, Sun et al (10) also 
showed that recombinant SDF-1 does not alter the growth rate 
of PC-3 cells under various conditions. However, an antibody to 
SDF‑1 significantly decreased the number of PC‑3 cells, which 
indicated that SDF-1 derived from the PC-3 cells themselves 
acts in an autocrine fashion to stimulate growth. Previous 
studies have demonstrated that SDF-1 stimulates the prolifera-
tion of small cell lung cancer cells (NCI-H69) in the presence 
of serum and colorectal cancer (SW480) and epithelial ovarian 
cancer (ES-2) cells in the absence of serum (26-28). In addi-
tion, antisense CXCR4 overexpression in glioblastoma cells 
has been shown to cause the inhibition of cell proliferation, 
indicating that the SDF-1/CXCR4 system is also involved 
in cell proliferation in glioblastoma cell lines (29,30). These 
differences may be due to different culture systems or target 
cells.
The effects of AMD3100 on the viability of tumor cells are 
controversial. In the present study, AMD3100 did not signifi-
cantly affect the viability of the PC-3 cells. Glioma (U251n), 
testicular germ cell tumor (TCAM2), epithelial ovarian cancer 
(ES-2) and oral squamous carcinoma (B88-SDF-1) cells have 
also been shown to be insensitive to AMD3100 (24,25,28,31). 
The enhancing effect of SDF-1 on cell proliferation was mark-
edly inhibited by AMD3100 treatment in colorectal cancer 
cells (SW480), but AMD3100 alone did not significantly affect 
cell proliferation when compared with the results observed in 
the SDF-1 unstimulated group, which indicated that there was 
no autocrine growth stimulatory loop in the cell line (27).
Although AMD3100 did not affect the viability of the 
PC-3 cells in the present study, it inhibited SDF-1-induced 
Akt activation. The Akt pathway is an important signaling 
pathway in prostate cancer (32,33). Akt is a serine-threonine 
kinase and its phosphorylation is linked to mitogenic 
signals. In addition to its role in survival, Akt participates 
in a number of intracellular pathways, including the integra-
tion of proliferation and differentiation signals that mediate 
migration and angiogenesis (16,32). To determine whether a 
CXCR4‑specific antagonist inhibits SDF‑1/CXCR4‑mediated 
Akt phosphorylation, in the present study, the PC-3 cells were 
pretreated with AMD3100. The phosphorylation of Akt in the 
AMD3100 pretreated cells was significantly lower than in the 
untreated cells and was similar to that observed in studies of 
cholangiocarcinoma cells (21). It has also been reported that 
in SDF-1-stimulated activation of ERK1/2 and Akt, rapid 
responses to SDF-1 are attenuated by AMD3100 in medul-
loblastoma and glioblastoma cells (Daoy and U87) (34).
The present results clearly demonstrate the inhibitory 
effects of a CXCR4‑specific antagonist on PC‑3 tumor growth 
in nude mice, although AMD3100 treatment had no direct 
effect on the proliferation of PC-3 cells in vitro. Previous studies 
have investigated the effects of CXCR4 antagonism on tumor 
growth and metastasis in other xenograft models. Such studies 
have observed that AMD3100 effectively inhibits anaplastic 
thyroid carcinoma tumor growth (35). Intraperitoneal treat-
ment with AMD3100 has been shown to result in reduced 
dissemination in nude mice inoculated with epithelial ovarian 
cancer cells (ES-2) (28). In an oral squamous cell carcinoma 
xenograft model, AMD3100 significantly inhibited lung 
metastasis of the SDF-1 transfectant, ameliorated body weight 
loss and improved the survival rates of tumor-bearing nude 
mice (31). Another anti-CXCR4 treatment, TN14003, has been 
shown to suppress primary tumor growth by inhibiting tumor 
angiogenesis and preventing lung metastasis of squamous cell 
carcinoma of the head and neck in animal models (36). The 
present study also showed that there was a marked reduction 
in microvessel formation in CXCR4 antagonist-treated tumors 
compared with tumors in the control group.
These marked differences in the biological effects of 
CXCR4 inhibition observed in animals and in cell culture may 
be explained by the fact that SDF-1 acts at multiple levels in 
the tumor microenvironment. Tumor stromal cells, including 
fibroblasts and bone marrow‑derived cells, express high levels 
of SDF-1, which may directly enhance the growth of epithelial 
tumor cells and recruit endothelial progenitors, thus favoring 
angiogenesis (37). It is believed that chronic treatment with 
AMD3100 efficiently blocks SDF‑1‑mediated vasculogenesis. 
Accordingly, the suppression of tumor growth in treated mice 
may be explained by the inhibition of CXCR4+ tumor cell 
proliferation and the diminishing recruitment of CXCR4+ 
angiogenic cells. The present study observed a strong inhibi-
tion of PC-3 tumor growth following AMD3100 treatment, 
but AMD3100 did not induce a complete regression of the 
tumors. Therefore, we hypothesize that combined treatment 
with AMD3100 and antineoplastic agents, such as platinum or 
taxanes, is a promising strategy.
No toxic effects of AMD3100 were detected in the animal 
model of the present study, but the appropriate therapeutic 
approach for antagonizing CXCR4 remains unclear, as 
long-term sustained dosing of AMD3100 results in some 
toxicity (38). A previous study showed that the sustained 
dosing of AMD3100 over a 10-day period was associated 
with mild toxicities. Reflecting the effects of AMD3100 
on bone marrow function, an elevation in white blood cell 
count was evident throughout an 18-day follow-up period 
following cessation of AMD3100 treatment (38). For these 
reasons, further studies aimed at understanding the effects 
of the long-term administration of CXCR4 inhibitors must 
be pursued. Despite these considerations, the present data, 
together with data from several other reports, markedly 
indicate that the inhibition of this pathway should be actively 
evaluated as a novel anticancer therapy. AMD3100 or other 
CXCR4‑specific inhibitors should be developed and tested as 
therapies for human prostate cancer.
In conclusion, the present study showed that the 
CXCR4-specific antagonist, AMD3100, effectively inhib-
ited SDF-1-induced CXCR4/Akt signal transduction in the 
PC-3 cells. Moreover, AMD3100 clearly suppressed tumor 
growth in the nude mice inoculated with the PC-3 cells, 
and AMD3100-treated PC-3 tumors showed lower levels of 
microvessel formation and a lower immunoreactivity for the 
proliferation marker Ki-67 and the anti-apoptotic marker 
Bcl-2 compared with control tumors in vivo. Thus, the study 
indicates that CXCR4 targeting may represent an effective 
strategy for the treatment of CRPC.
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